ResMed Inc.'s recent
earnings reports have resulted in a flurry of increased price targets from banks, key analysts and
investment firms, including
J.P. Morgan and
Keybanc. The company's
Q4 earnings surpassed both earnings and revenue estimates. Predictions place the value of ResMed's stock between
$290 to $325. The company registered considerable revenue growth for
Q2 and Q3 of 2025, despite pandemic hardships.
Stock performance has attracted attention from stock market pundits and investors alike. However, while the company's earnings beat financial forecasts, revenue fell short of expectations. This mixed performance led to varied views on the company's future, with further uncertainty surrounding the recent
resignation of ResMed’s
CCO Bobby Ghoshal. Amid this, ResMed did increase
quarterly dividends, benefitting investors and signalling a positive financial position. Despite
mixed technical outlooks, analysts remain optimistic about
ResMed's strong fundamentals. Encouraging
growth rates assert ResMed as a top-ranked stock, drawing
investment interest for its long-term potential. ResMed has also made a strategic acquisition of
VirtuOx.
Resmed RMD News Analytics from Mon, 23 Dec 2024 08:00:00 GMT to Sat, 02 Aug 2025 16:42:42 GMT -
Rating 7
- Innovation 6
- Information 9
- Rumor 3
